Stay updated with breaking news from Hans Moebius. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Completed enrollment in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease and expects topline data in second half of 2024 Plans to...
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative...
Researchers are evaluating the safety and efficacy of fosgonimeton in patients with mild to moderate Alzheimer disease.
Researchers are evaluating the safety and efficacy of fosgonimeton in patients with mild to moderate Alzheimer disease.
01.02.2023 - BOTHELL, Wash., Feb. 01, 2023 (GLOBE NEWSWIRE) - Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the ... Seite 1